31 results about "Erdosteine" patented technology

The invention provides an Erdosteine composition which consists of the following components by weight portions: 130 to 170 portions of Erdosteine, 35 to 65 portions of lactose, 30 to 70 portions of microcrystalline cellulose, 20 to 40 portions of low substituted hydroxypropyl cellulose, 1 to 5 portions of acesulfame, 10 to 30 portions of sodium carboxymethyl starch and 0.1 to 0.5 portions of magnesium stearate; the invention also provides a preparation method of the Erdosteine composition, comprising the following steps of: preparing materials and pelleting; mixing the Erdosteine and the low substituted hydroxypropyl cellulose evenly, then grinding, adding the sodium carboxymethyl starch, adding absolute ethyl alcohol, wet-mixing, cutting, drying, granulation and tabletting; mixing granules and microcrystalline cellulose evenly, adding the lactose, the acesulfame and the magnesium stearate for pelleting, subpackaging and obtaining the Erdosteine composition. The Erdosteine compositionhas good dispersible uniformity and high drug dissolution efficiency.

The invention discloses a preparation method of thioglycolic anhydride, which comprises the following steps: vaporization of trifluoroacetic anhydride: vaporizing trifluoroacetic anhydride in a vaporization device for use; synthesis of thioglycolic anhydride: After the internal temperature of the suspended gas-solid reaction device is preheated to 45-65°C, the vaporized trifluoroacetic anhydride is passed into the suspended gas-solid reaction device, and sulfide disulfide is intermittently added from the top of the suspended gas-solid reaction device. Acetic acid, after reacting for 2 hours, stop feeding vaporized trifluoroacetic anhydride from the air inlet, stop heating, and the solid product obtained is derived from the discharge port; the purification of thioglycolic anhydride: use the solid product respectively with refrigerated Wash with anhydrous petroleum ether and anhydrous ether to obtain pure thioglycolic anhydride. The thioglycolic anhydride synthesized by the invention has high purity and high yield, and the erdosteine ​​produced by reacting the thioglycolic anhydride as a raw material with homocysteine ​​thiolactone hydrochloride has a high yield.

The invention relates to an erdosteine dispersing tablet for treating diseases of respiratory systems and a method for preparing the dispersing tablets. The erdosteine dispersing tablet comprises erdosteine, hydroxy propyl celluloses, sodium carboxymethyl starch, polyethylene glycol 4000-6000, microcrystalline celluloses 102, crospovidone, magnesium stearate and povidone K30. The erdosteine is erdosteine monohydrate, a molecular formula of the erdosteine is C8H11NO4S2.H2O, and characteristic diffraction peaks are displayed at 3.323, 8.484, 12.661, 21.823, 30.645, 31.161, 33.209, 36.161 and 38.935 positions of X-ray powder diffraction spectra expressed at diffraction angles of 2 theta+ / -0.2 degrees. As discovered in tests, the erdosteine dispersing tablet and the method have the advantages that the erdosteine dispersing tablet is good in stability and high in bioavailability, and problems of poor solubility and compressibility, sticking easiness in production procedures and the like of erdosteine dispersing tablets in the prior art can be solved.

The present invention provides novel crystalline polymorphs of enantiopure Erdosteine, referred to as Form I and Form II, and processes for the preparation thereof.

The invention discloses an erdosteine ​​compound for treating respiratory inflammation and a preparation method thereof, belonging to the technical field of medicine. The X-ray powder diffraction pattern obtained by measuring the erdosteine ​​compound using Cu-Kα rays is shown in Figure 1. The erdosteine ​​crystal provided by the invention has stable chemical properties, good water solubility and high stability, brings convenience to the preparation of various preparations, and is very suitable for clinical application.

The invention relates to ambroxol, erdosteine or the medicinal composition of the pharmaceutically usable salts of the two and their use, ambroxol and acetylcysteine or the medicinal composition of the pharmaceutically usable salts of the two and their use, the kit containing these compositions, and the use of these pharmaceutical compositions in preparing expectorant medicaments. The invention also relates to the cooperative compositions of ambroxol and erdosterne, ambroxol and acetylcysteine, and the use of these cooperative compositions in treating viscous phlegm and phlegm difficulty caused by chronic bronchitis and bronchial asthma.